Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cancer Genetics nets $6.4mm through its IPO

Executive Summary

After a series of postponements and amendments, diagnostics firm Cancer Genetics Inc. has finally completed its initial public offering, netting $6.4mm through the sale of 690k common shares (including the overallotment) at $10. The company initially filed in December 2011, and at different points over the 16 months had set intended ranges for the offering of anywhere from $6-13 per share, with hopes of selling between 600k and 5mm shares.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
    • Esoteric Laboratories
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies